Novo Nordisk shares fall on latest trial results for new obesity drug
Shares in Novo Nordisk fell on Monday on a second set of worse than expected trial results for the latest obesity drug from the manufacturer of blockbuster treatments Ozempic and Wegovy. The trial of CagriSema in patients who were obese or overweight and with type 2 diabetes failed to show a clear superiority to a drug from rival Eli Lilly,
Zacks Investment Research on MSN18h
NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With ZealandNovo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 ...
Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...
Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...
Zacks Investment Research on MSN19h
Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline UpdateNovo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche RHHBY ...
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a ...
A long-term Novo Nordisk A/S skeptic recommended buying shares of the Danish weight-loss drug maker nine years after starting ...
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback